Abstract
Genetic variants of SARS-CoV-2 have been emerging and circulating in many places across the world. Rapid detection of these variants is essential since their dissemination can impact transmission rates, diagnostic procedures, disease severity, response to vaccines or patient management. Sanger sequencing has been used as the preferred approach for variant detection among circulating human immunodeficiency and measles virus genotypes. Using primers to amplify a fragment of the SARS-CoV-2 genome encoding part of the Spike protein, we showed that Sanger sequencing allowed us to rapidly detect the introduction and spread of three distinct SARS-CoV-2 variants in two major Brazilian cities. In both cities, after the predominance of variants closely related to the virus first identified in China, the emergence of the P.2 variant was quickly followed by the identification of the P1 variant, which became dominant in less than one month after it was first detected.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Brazilian Ministry of Science, Technology and Innovation (MCTI) through the Rede Virus initiative and its many individual projects: Sub-rede Coronaomica, sub-rede Diagnostico, sub-rede Laboratorios de Campanha. The research leading to these results also received funding from the Secretaria de Ensino Superior do Ministerio da Educacao [grant number SEI 23072.211119/2020-10], from FAPEMIG (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais), Finep (Financiadora de Estudos e Projetos), from Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior (CAPES), from CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico), from FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) [Project 2020/06409-1] as well as from the Sociedade Beneficiente Israelita Brasileira Hospital Albert Einstein and Associacao Brasileira de gestao em projetos. GPS, EGD, BLT, FGF, SMRT, APF are recipients of CNPq fellowships.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Part of study involving samples from Sao Paulo city was approved by Instituto de Ciencias Biomedicas ethical committee. CAAE number: 32712620.9.0000.5467. The study involving samples from Belo Horizonte was approved by the UFMG Ethics Committee, CAAE- 35074720.3.0000.5149.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
